TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The OpenAPS_ShadowMode Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Aged ≥ 18 years~* T1D as defined by WHO for at least 1 year~* Planned use of the Medtronic 670G HCL system~Exclusion Criteria:~* Type 2 diabetes mellitus~* Gestational diabetes mellitus~* Participation in another trial which may in the opinion of the investigator interfere with the software algorithm~* Any mental condition rendering the patient incapable of giving informed consent~* Any disease or condition which in the opinion of the investigator would interfere with the trial performance and/or the physical and/or psychosocial safety of the study participant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 670G/OpenAPS (Type: None): Participants with Type 1 Diabetes wearing a Medtornic Minimed 670G hybrid closed loop system in parallel with a non-insulin injecting, self-constructed OpenAPS system.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Mucopolysaccharidosis type VI (MPS VI, Maroteaux-Lamy syndrome) treated with a prior allogeneic transplant \>2 years previously~* Persons currently receiving Naglazyme may be accepted into the study~* Age \> 2 years~* \>10% engrafted based on most recent testing~* Willing to commit to traveling to the University of Minnesota every 6 months~* Written informed consent with parent/guardian consent for children \< 18 years of age or persons unable to consent with minor assent if appropriate~Exclusion Criteria:~* History of cardiac or pulmonary insufficiency or those requiring continuous supplemental oxygen~* Pregnant or breastfeeding~* Any condition that, in the view of the investigator, places the patient at high risk of poor treatment compliance or of not completing the study

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Naglazyme® (Type: EXPERIMENTAL): weekly Naglazyme® infusion for 2 years

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Follow-up Study in Patients With Inherited Metabolic Disorders (IMD) Who Underwent Hematopoietic Stem Cell Transplantation (HSCT) With MGTA-456

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* An Institutional Review Board (IRB)/Independent Ethics Committee-approved written informed consent form must be signed and dated by the patient or legal guardian. Study assents will also be prepared for children and adolescents to review when applicable.~* Patient completed an IMD study in the MGTA-456 program and was administered MGTA-456 for HSCT.~Exclusion Criteria:~•Patients enrolled in an IMD study in the MGTA-456 program who did not receive MGTA-456 or were withdrawn from the core study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Subjects treated with MGTA-456 (Type: None): MGTA-456 is an investigational expanded CD34+ cell therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Preliminary Efficacy of Adipose Derive Stem Cells for Patients With COPD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and Females ≥18 years.~2. Cognitive competitiveness.~3. Diagnosis of at least moderate COPD (postbronchodilator FEV1/FVC \< 70% (\<0.7), FEV1 \< 80% predicted).~4. Diffusing capacity impairment (DLCO) assessed by single breath test (corrected for alveolar volume, 'DLVA').~5. Life expectancy greater than 12 months.~6. Ability to understand and provide signed informed consent, or have a designated legal guardian or spouse legally able and willing to make such decisions on the subject's behalf.~7. Reasonable expectation that patient will receive standard post-treatment care and attend all scheduled safety follow-up visits.~8. No changes in active pulmonary medications for heart failure during the two weeks prior enrollment.~10. Written informed consent. 11. Non-smoker or Past smoker, with 20 pack-years or more history~Exclusion Criteria:~1. Current smokers.~2. Unstable coronary disease.~3. Patients with industrial exposure to silica and/or asbestos or giant bullae.~4. Uncontrolled seizure disorder.~5. Dementia.~6. Presence of immune deficiency or autoimmune disease.~7. Alpha- 1 antitrypsin deficiency.~8. Cor pulmonale or diastolic heart failure NYHA class III or IV~9. Type 1 diabetes mellitus~10. Complicated type 2 diabetes mellitus.~11. Active tuberculosis or severe lung damage due to tuberculosis (extensive cavitation).~12. History of cancer within the past 5 years.~13. Clinically-significant hematologic, hepatic, or renal impairment as determined by screening clinical laboratory tests.~14. Systemic corticosteroids, cytostatics, immunosuppressive drug therapy (cyclophosphamide, methotrexate, cyclosporine, azathioprine, etc.), and DNA depleting or cytotoxic drugs taken within four weeks prior to study treatment.~15. Porphyria.~16. Allergy to sodium citrate or any caine type of local anesthetic.~17. Abnormal findings could include: known HIV infection or other immunodeficiency state, chronic active viral infection (such as hepatitis B or C), acute systemic infections (defined as patients undergoing treatment with antibiotics), gastrointestinal tract bleeding, or any severe or acute concomitant illness or injury.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ADSCs administration (Type: EXPERIMENTAL): Patients with Chronic Obstructive Pulmonary Disease will be treated with a single dose of autologous adipose derived stem cells. Stem cells will be isolated using standard Lipoaspiration procedure under sterile conditions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Burden of Obstructive Sleep Apnea in Stroke (BOSAST)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* stroke survivor in stroke rehabilitation unit~* age 45-85~* able to consent~* no prior treatment with CPAP~Exclusion Criteria:~* complex apnea~* known inflammatory disease~* neurological disease precluding patient's ability to consent and cooperate

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- CPAP (Type: ACTIVE_COMPARATOR): CPAP at therapeutic pressure
- sub-therapeutic CPAP (Type: SHAM_COMPARATOR): CPAP administered at sub-therapeutic pressure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Natera Ovarian Cancer Detection Assay

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Presenting to clinic with adnexal mass suspicious of ovarian, fallopian tube, or peritoneal cancer on imaging~* Must be planning surgical resection or biopsy~* Must be treatment naïve~* Must be 18 years or older~* Able to understand and sign a written informed consent document~* Able to provide 40mL of blood (at least 20mL) for each blood draw~Exclusion Criteria:~* Prior removal of either ovary for any reason~* Currently pregnant~* Blood transfusion within 3 months of study enrollment~* History of bone marrow or organ transplant~* Prior history and treatment for any malignancy, with exception of previously treated non-melanoma skin cancer.~* A medical condition that would place subject at risk as a result of the blood donation, including but not limited to bleeding disorders, chronic infectious disease, emphysema or serious anemia

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* Inclusion Criteria~* Diagnosis of advanced or metastatic NSCLC. Group A must be ALK negative NSCLC and Group B must be ALK positive NSCLC~* Group A at least one prior regimen of therapy~* Group B any number of prior regimens.~* Mandatory tumor tissue available~* At least one measurable lesion~* ECOG Performance status 0 or 1~* Adequate bone marrow, renal, liver and pancreatic function~* Negative pregnancy test for females of childbearing potential~* Group B Phase 2: No prior systemic treatment for advanced or metastatic disease (adjuvant and/or neoadjuvant therapies are allowed if completed at least 6 months prior to study entry. No prior tyrosine kinase inhibitor therapy is allowed at any time prior to study entry)~Exclusion Criteria:~* No prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody.~* No Severe or Chronic medical conditions including gastrointestinal abnormalities or significant cardiac history~* No active infection requiring systemic therapy~* Prior organ transplantation including allogenic stem cell transplantation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): ALK negative Non-Small Cell Lung Cancer
- Group B (Type: EXPERIMENTAL): ALK positive Non-Small Cell Lung Cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Very Preterm Children With Language Delay and Parent Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Child born at 24 to 31+6 weeks' gestation, whose parents did not refuse collection of follow-up data~* Child aged 30 ± 2 months corrected age (CA) at inclusion~* Child with language delay at 24 months CA, defined as the absence of word combination and/or expressive vocabulary of less than 30 words according to the short version of the French Mac Arthur Communication Developmental Inventories (CDI), whose language delay is confirmed at 30 months CA i.e. without word combination and/or an expressive vocabulary below the 10th percentile on the French CDI.~* Child with a global Developmental Quotient (DQ) ≥ 55 at 30 months CA~* Child whose parents accept participation in this study~* Child with French health insurance coverage~Exclusion Criteria:~* Child with neurological sequelae (delay or disability) and who is unable to walk without assistance at 24 months CA or who has a global DQ \< 55 on the revised Brunet-Lézine (BLR) scale at 30 months CA.~* Blindness~* Deafness defined by the prescription of a hearing aid~* Child with a chromosomal or other condition that could interfere with language development~* Parents who do not speak French at all~* Triplets

- Gender: ALL
- Minimum Age: 28 Months
- Maximum Age: 32 Months
- Healthy Volunteers: f

Study Arms:
- Parent-implemented language intervention (Type: EXPERIMENTAL): In the intervention group, the techniques and attitudes favouring use of oral language will be taught to the parents during 15 sessions with the parent(s) and child.
- Control group (Type: NO_INTERVENTION): The control group will benefit from the actual routine care for children with language delay before the age of 3 years. In order to provide them the best routine care, the psychologist will provide some advice to the parents to enhance their child's language (e.g.: using life situations to talk with the child and encourage him/her to talk ...).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: New Method for Distal Interlocking of Cannulated Intramedullary Nails

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signing Informed consent.~2. Conscious patients.~Exclusion Criteria:~1. Hemodynamic Instability.~2. Multiple system injuries.~3. Pregnancy.~4. Soldiers.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Banding Ligation With Carvedilol Versus Carvedilol for the Prevention of First Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Cirrhosis with esophageal varices are larger than F2.~2. No history of variceal bleeding.~3. In three months have not implemented preventive esophageal variceal ligation. (4)age 20yrs～75yrs.~Exclusion Criteria:~1. Association with HCC or other cancers .~2. Refractory ascites.~3. Jaundice, bilirubin \> 5mg/dl.~4. Encephalopathy.~5. Cr.\>3mg/dL.~6. A-V,block bradycardia (PR \< 60/mim).~7. Hypotension systolic blood pressure\<95/mmHg .~8. Refusal to participate.~9. Carvedilol allergy~10. Second degree-third degree Atrio-ventricular block.~11. Bradycardia.~12. WPWsyndrome~13. Hypotension~14. Psychogenic shock.~15. Asthma. All the patients are randomized based on a random number.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- EVL + carvedilol (Type: EXPERIMENTAL): EVL is performed for 2-3 times carvedilol 6.25mg-12.5 mg per day
- carvedilol (Type: ACTIVE_COMPARATOR): carvedilol 6.25-12.5 mg per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transcranial Direct Current Stimulation (tDCS) to Improve Gesture Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Right handed according to the Edinburgh Handedness Inventory~* Ability and willingness to participate in the study~* Ability to provide written informed consent~* Informed Consent as documented by signature (Appendix Informed Consent Form)~* Spent majority of childhood/adolescence in Switzerland~* Patients: schizophrenia spectrum disorder according to DSM-5~Exclusion Criteria:~* Women who are pregnant or breast feeding~* Metal objects on or in the body (e.g. grenade splinter, cardiac pacemaker, vessel clips, metal prostheses, contraceptive coil, cochlear implants, hearing aid, tooth implant)~* Tattoos on head, neck or shoulder in close proximity to the electrode placement~* Current skin problems on the scalp, eg. bruises or open wounds~* History of neurosurgery, any severe head wounds, history of neurologic disorders impacting gesture, e.g. Parkinson's disease, stroke, multiple sclerosis~* Active drug addiction except nicotine~* Known contact allergies~* Controls: first-degree relatives with schizophrenia spectrum disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- left IFG anodal (Type: EXPERIMENTAL): 2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
- left IFG cathodal (Type: ACTIVE_COMPARATOR): 2 mA Stimulation of 10 min, cathodal electrode over left IFG, anodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
- left IPL anodal (Type: ACTIVE_COMPARATOR): 2 mA Stimulation of 10 min, anodal electrode over left IPL, cathodal electrode over right IPL, 30 sec ramp to start and 30 sec ramp to stop
- left IPL cathodal (Type: ACTIVE_COMPARATOR): 2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
- Placebo (Type: PLACEBO_COMPARATOR): anodal electrode over left IFG, cathodal electrode over right IFG, stimulation only during 30 sec ramp at beginning and end of 10 min

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transcranial Laser Therapy in the Rehabilitation of Hemiplegic Patients From Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with hemiplegia secondary to cerebral stroke ischemic.~2. Requirement of shaving the scalp area.~3. Initiation of the TLT procedure begins between 70 and 100 days after stroke onset.~4. Informed written consent before enrolling in the study.~Exclusion Criteria:~1. Hemiplegia secondary to hemorrhagic stroke.~2. Metallic brain implants.~3. Neurodegenerative disorders.~4. Bilateral motor problems.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Transcranial low level laser therapy (Type: EXPERIMENTAL): Transcranial laser therapy is applied by automatic scanning over both hemispheres and the patients undergoing also a standard rehabilitation program based on therapeutic exercises.
- Control (Type: ACTIVE_COMPARATOR): The patients undergoing only a standard rehabilitation program based on therapeutic exercises.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: IV Contrast-Enhanced Cone Beam Computed Tomography (CBCT) in Radiotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject must be greater than or equal to 18 years of age.~2. Subject must be able and willing to sign a written informed consent document.~3. Subject requiring image-guided external beam radiotherapy to abdominal or pelvic tumor with cone beam CT deemed clinically necessary by the treating physician.~4. No history of prior allergic reaction to intravenous CT contrast medium.~5. Creatinine of less than 1.9 mg/dL measured within one month prior to enrollment on the study.~6. No administration of intravenous contrast within 24 hours of administration of intravenous contrast on protocol.~7. Ability to complete New York Presbyterian Hospital iodinated contrast media administration questionnaire.~8. Negative pregnancy test for females of childbearing potential, in accordance to institutional guidelines.~9. Ability to fast for at least 2 hours prior to study procedures.~10. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-3.~Exclusion Criteria:~1. Known allergy to iohexol or any iodinated intravenous contrast medium.~2. Fluid overload that would contraindicate bolus administration of intravenous contrast.~3. Pregnant or nursing subjects.~4. Presence of single kidney or transplanted kidney~5. Acute renal failure~6. Chronic renal insufficiency, stage IV or V.~7. Administration of iodinated intravenous CT contrast medium within 24 hours of study procedures.~8. Inability to fast for at least 2 hours prior to study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Contrast Enhanced Cone Beam CT (Type: EXPERIMENTAL): 60 seconds after the start of the administration of IV contrast, cone beam CT will be initiated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of RAM Cannula Nasal Continuous Positive Airway Pressure Versus Infant Flow Nasal Continuous Positive Airway Pressure (NCPAP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* less than or equal to 7 kg~* order for nasal continuous positive pressure~Exclusion Criteria:~* patients greater than 7kg~* patients that do not have informed consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- RAM Cannula Nasal Continuous Positive Airway Pressure (Type: None): None
- Infant Flow Nasal Continuous Positive Airway Pressure (NCPAP) (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility